1 Market Overview

• 1.1 Product Overview and Scope of Enasidenib
• 1.2 Market Estimation Caveats and Base Year
• 1.3 Market Analysis by Type
  • 1.3.1 Overview: Global Enasidenib Consumption Value by Type: 2019 Versus 2023 Versus 2030
  • 1.3.2 50mg
  • 1.3.3 100mg
• 1.4 Market Analysis by Application
  • 1.4.1 Overview: Global Enasidenib Consumption Value by Application: 2019 Versus 2023 Versus 2030
  • 1.4.2 Hospital
  • 1.4.3 Pharmacy
• 1.5 Global Enasidenib Market Size & Forecast
  • 1.5.1 Global Enasidenib Consumption Value (2019 & 2023 & 2030)
  • 1.5.2 Global Enasidenib Sales Quantity (2019-2030)
  • 1.5.3 Global Enasidenib Average Price (2019-2030)

2 Manufacturers Profiles

• 2.1 Bristol Myers Squibb
  • 2.1.1 Bristol Myers Squibb Details
  • 2.1.2 Bristol Myers Squibb Major Business
  • 2.1.3 Bristol Myers Squibb Enasidenib Product and Services
  • 2.1.4 Bristol Myers Squibb Enasidenib Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
  • 2.1.5 Bristol Myers Squibb Recent Developments/Updates

3 Competitive Environment: Enasidenib by Manufacturer

• 3.1 Global Enasidenib Sales Quantity by Manufacturer (2019-2024)
• 3.2 Global Enasidenib Revenue by Manufacturer (2019-2024)
• 3.3 Global Enasidenib Average Price by Manufacturer (2019-2024)
• 3.4 Market Share Analysis (2023)
  • 3.4.1 Producer Shipments of Enasidenib by Manufacturer Revenue ($MM) and Market Share (%): 2023
  • 3.4.2 Top 3 Enasidenib Manufacturer Market Share in 2023
  • 3.4.2 Top 6 Enasidenib Manufacturer Market Share in 2023
• 3.5 Enasidenib Market: Overall Company Footprint Analysis
  • 3.5.1 Enasidenib Market: Region Footprint
  • 3.5.2 Enasidenib Market: Company Product Type Footprint
  • 3.5.3 Enasidenib Market: Company Product Application Footprint
• 3.6 New Market Entrants and Barriers to Market Entry
• 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

• 4.1 Global Enasidenib Market Size by Region
  • 4.1.1 Global Enasidenib Sales Quantity by Region (2019-2030)
  • 4.1.2 Global Enasidenib Consumption Value by Region (2019-2030)
  • 4.1.3 Global Enasidenib Average Price by Region (2019-2030)
• 4.2 North America Enasidenib Consumption Value (2019-2030)
• 4.3 Europe Enasidenib Consumption Value (2019-2030)
• 4.4 Asia-Pacific Enasidenib Consumption Value (2019-2030)
• 4.5 South America Enasidenib Consumption Value (2019-2030)
• 4.6 Middle East and Africa Enasidenib Consumption Value (2019-2030)

5 Market Segment by Type

• 5.1 Global Enasidenib Sales Quantity by Type (2019-2030)
• 5.2 Global Enasidenib Consumption Value by Type (2019-2030)
• 5.3 Global Enasidenib Average Price by Type (2019-2030)

6 Market Segment by Application

• 6.1 Global Enasidenib Sales Quantity by Application (2019-2030)
• 6.2 Global Enasidenib Consumption Value by Application (2019-2030)
• 6.3 Global Enasidenib Average Price by Application (2019-2030)

7 North America

• 7.1 North America Enasidenib Sales Quantity by Type (2019-2030)
• 7.2 North America Enasidenib Sales Quantity by Application (2019-2030)
• 7.3 North America Enasidenib Market Size by Country
  • 7.3.1 North America Enasidenib Sales Quantity by Country (2019-2030)
  • 7.3.2 North America Enasidenib Consumption Value by Country (2019-2030)
  • 7.3.3 United States Market Size and Forecast (2019-2030)
  • 7.3.4 Canada Market Size and Forecast (2019-2030)
  • 7.3.5 Mexico Market Size and Forecast (2019-2030)

8 Europe

• 8.1 Europe Enasidenib Sales Quantity by Type (2019-2030)
• 8.2 Europe Enasidenib Sales Quantity by Application (2019-2030)
• 8.3 Europe Enasidenib Market Size by Country
  • 8.3.1 Europe Enasidenib Sales Quantity by Country (2019-2030)
  • 8.3.2 Europe Enasidenib Consumption Value by Country (2019-2030)
  • 8.3.3 Germany Market Size and Forecast (2019-2030)
  • 8.3.4 France Market Size and Forecast (2019-2030)
  • 8.3.5 United Kingdom Market Size and Forecast (2019-2030)
  • 8.3.6 Russia Market Size and Forecast (2019-2030)
  • 8.3.7 Italy Market Size and Forecast (2019-2030)

9 Asia-Pacific

• 9.1 Asia-Pacific Enasidenib Sales Quantity by Type (2019-2030)
• 9.2 Asia-Pacific Enasidenib Sales Quantity by Application (2019-2030)
• 9.3 Asia-Pacific Enasidenib Market Size by Region
  • 9.3.1 Asia-Pacific Enasidenib Sales Quantity by Region (2019-2030)
  • 9.3.2 Asia-Pacific Enasidenib Consumption Value by Region (2019-2030)
  • 9.3.3 China Market Size and Forecast (2019-2030)
  • 9.3.4 Japan Market Size and Forecast (2019-2030)
  • 9.3.5 Korea Market Size and Forecast (2019-2030)
  • 9.3.6 India Market Size and Forecast (2019-2030)
  • 9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
  • 9.3.8 Australia Market Size and Forecast (2019-2030)

10 South America

• 10.1 South America Enasidenib Sales Quantity by Type (2019-2030)
• 10.2 South America Enasidenib Sales Quantity by Application (2019-2030)
• 10.3 South America Enasidenib Market Size by Country
  • 10.3.1 South America Enasidenib Sales Quantity by Country (2019-2030)
  • 10.3.2 South America Enasidenib Consumption Value by Country (2019-2030)
  • 10.3.3 Brazil Market Size and Forecast (2019-2030)
  • 10.3.4 Argentina Market Size and Forecast (2019-2030)

11 Middle East & Africa

• 11.1 Middle East & Africa Enasidenib Sales Quantity by Type (2019-2030)
• 11.2 Middle East & Africa Enasidenib Sales Quantity by Application (2019-2030)
• 11.3 Middle East & Africa Enasidenib Market Size by Country
  • 11.3.1 Middle East & Africa Enasidenib Sales Quantity by Country (2019-2030)
  • 11.3.2 Middle East & Africa Enasidenib Consumption Value by Country (2019-2030)
  • 11.3.3 Turkey Market Size and Forecast (2019-2030)
  • 11.3.4 Egypt Market Size and Forecast (2019-2030)
  • 11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
  • 11.3.6 South Africa Market Size and Forecast (2019-2030)

12 Market Dynamics

• 12.1 Enasidenib Market Drivers
• 12.2 Enasidenib Market Restraints
• 12.3 Enasidenib Trends Analysis
• 12.4 Porters Five Forces Analysis
  • 12.4.1 Threat of New Entrants
  • 12.4.2 Bargaining Power of Suppliers
  • 12.4.3 Bargaining Power of Buyers
  • 12.4.4 Threat of Substitutes
  • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

• 13.1 Raw Material of Enasidenib and Key Manufacturers
• 13.2 Manufacturing Costs Percentage of Enasidenib
• 13.3 Enasidenib Production Process
• 13.4 Enasidenib Industrial Chain

14 Shipments by Distribution Channel

• 14.1 Sales Channel
  • 14.1.1 Direct to End-User
  • 14.1.2 Distributors
• 14.2 Enasidenib Typical Distributors
• 14.3 Enasidenib Typical Customers

15 Research Findings and Conclusion

16 Appendix

• 16.1 Methodology
• 16.2 Research Process and Data Source

According to our (Global Info Research) latest study, the global Enasidenib market size was valued at USD 81 million in 2023 and is forecast to a readjusted size of USD 127.6 million by 2030 with a CAGR of 6.8% during review period.
Enasidenib is a drug used to treat relapsed or refractory acute myeloid leukemia in people with specific mutations of the isocitrate dehydrogenase 2 (IDH2) gene, determined by an FDA-approved IDH2 companion diagnostic test
Enasidenib is a targeted therapy used to treat relapsed or refractory acute myeloid leukemia (AML) with an IDH2 mutation. Its efficacy in inhibiting the mutated IDH2 enzyme and inducing remission has driven market growth. The limited treatment options for this specific subset of AML contribute to its niche status. However, challenges include potential side effects and the need for genetic testing to identify eligible patients. The market competition is relatively small, as Enasidenib remains a targeted therapy for a specific AML subgroup. Despite challenges, the Enasidenib market offers potential for growth as healthcare providers seek effective treatments for patients with IDH2-mutated AML. Continued research and clinical advancements can further drive market expansion.
The Global Info Research report includes an overview of the development of the Enasidenib industry chain, the market status of Hospital (50mg, 100mg), Pharmacy (50mg, 100mg), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Enasidenib.
Regionally, the report analyzes the Enasidenib markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Enasidenib market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Enasidenib market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Enasidenib industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (Units), revenue generated, and market share of different by Type (e.g., 50mg, 100mg).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Enasidenib market.
Regional Analysis: The report involves examining the Enasidenib market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Enasidenib market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Enasidenib:
Company Analysis: Report covers individual Enasidenib manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Enasidenib This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospital, Pharmacy).
Technology Analysis: Report covers specific technologies relevant to Enasidenib. It assesses the current state, advancements, and potential future developments in Enasidenib areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Enasidenib market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Enasidenib market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
50mg
100mg
Market segment by Application
Hospital
Pharmacy
Major players covered
Bristol Myers Squibb
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Enasidenib product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Enasidenib, with price, sales, revenue and global market share of Enasidenib from 2019 to 2024.
Chapter 3, the Enasidenib competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Enasidenib breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2023.and Enasidenib market forecast, by regions, type and application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Enasidenib.
Chapter 14 and 15, to describe Enasidenib sales channel, distributors, customers, research findings and conclusion.